Dr Antony Workman

- Senior Lecturer (Institute of Cardiovascular and Medical Sciences)
telephone: 01413303451
email: Antony.Workman@glasgow.ac.uk
Tony Workman graduated in 1988 with a BSc in Animal Physiology from London University. Awarded PhD in Cardiovascular Pharmacology, De Montfort University, Leicester, 1996. Postdoctoral Research Fellow at Glasgow University, 1996, investigating effects of adenosine on atrioventricular nodal and atrial cellular electrophysiology. Awarded British Heart Foundation Basic Science Lectureship in 2001, investigating human atrial cellular electrophysiological remodelling in atrial fibrillation. Appointed non-clinical lecturer in 2001. Awarded Postgraduate Certificate in Academic Practice, 2004. Co-ordinator of intercalated degree in Cardiovascular Studies, and PhD supervisor. Renewed BHF lectureship 2006, investigating human atrial pharmacological remodelling by beta-blockers. Secured tenured post at Glasgow University in 2006. Appointed Senior Lecturer in 2010.
Atrial fibrillation (AF) is a disorder of the rhythm of the heart’s upper chambers. This disease affects 1 in 20 people aged over 65, and decreases their life expectancy. My research aims to improve our understanding of the electrophysiological and molecular mechanisms of AF, in the hope that this will lead to more effective treatments. I have obtained external funding for this research through British Heart Foundation Basic Science Lectureship Awards and collaborative grants.
I have demonstrated that electric currents and voltage signals generated by single heart cells obtained from patients with AF are disturbed in a way that may exacerbate the disease, by “electrical remodelling”. For example, the atrial cell’s refractory period is reduced (Fig), which may promote a rapid and chaotic rhythm. Circulating levels of catecholamines, serotonin and endothelin are elevated in patients with AF and heart failure. Endothelin inhibited voltage oscillations caused by catecholamines -a potentially beneficial influence in AF, and a potentially pro-arrhythmic action of serotonin was reduced in patients with AF. Beta-blockers prevent AF in some patients, although the mechanism is unclear. I have identified an adaptive response to chronic beta-blocker therapy in human atrial cells. This “pharmacological remodelling”, including prolongation of the refractory period, may contribute to anti-arrhythmic actions of these drugs. Current investigations focus on effects of beta-blockade, and of heart failure, on electric currents, calcium movements and the proteins which regulate these, in human atrial cells and tissues.
Research:
Member:
Grants and Awards listed are those received whilst working with the University of Glasgow.
- Atrial remodelling of calcium handling and electrophysiology in heart failure.
British Heart Foundation
2009 - 2013
- Atrial myocardial adaptation to prolonged beta-adrenoceptor antagonism in normal and failing hearts
British Heart Foundation
2006 - 2011
- Human atrial cellular calcium handling, arrhythmogenic mechanisms of 5-hydroxytryptamine, and their modulation by atrial fibrillation
British Heart Foundation
2004 - 2007
- Atrial fibrillation-induced ion currents and mRNA levels in the human atrium
British Heart Foundation
2001 - 2006
Invited International Presentations
- 2012: Birmingham, UK - Heart Rhythm UK - "Atrial cellular remodelling by heart disease, arrhythmias and drugs"
- 2012: Manchester, UK - Physiological Society - "Mechanisms of human atrial fibrillation: insights from cellular electrophysiology studies"
- 2010: Atlanta, GA, USA - American College of Cardiology - "Remodelling of the action potential in atrial fibrillation"
- 2010: Santa Monica, CA, USA - California Heart Rhythm Symposium - "Cellular basis of atrial fibrillation"
- 2009: London, UK - Recent Developments in Interventional Cardiology, associated with Br J Hosp Med - "Causes and mechanisms of atrial fibrillation and ventricular arrhythmias"
- 2009: Orlando, FL, USA - American College of Cardiology - "Electrical Remodeling in Atrial Fibrillation"
- 2009: Dresden, Germany - British Pharmacological Society & German Societies for Pharmacology and Clinical Pharmacology - "Cardiac adrenergic control and atrial fibrillation"
- 2007: Santa Monica, CA, USA - California Heart Rhythm Symposium - "Cellular bases for human atrial fibrillation"
- 2005: Prague, Czech Republic - Europace - "Remodelling the potassium sodium pump during atrial fibrillation"
- 2003: Vienna, Austria - Vascular Biology Working Group - "Chronic beta-adrenoceptor blockade and human atrial cell electrophysiology: Evidence of pharmacological remodeling"
